Aastrom Biosciences Inc.

George Dunbar joined Aastrom in 2006 and serves as Chief Executive Officer, President, Chief Financial Officer and a member of the Company's Board of Directors. Over the last 15 years, Mr. Dunbar served as Chief Executive Officer and Director of Quantum Dot Corporation, Targesome, Inc., and Epic Therapeutics; as Acting President and Chief Executive Officer of StemCells, Inc. (formerly CytoTherapeutics); and as President and Chief Executive Officer of Metra Biosystems, Inc. Prior to that time, Mr. Dunbar held senior positions in licensing, business development and marketing with The Ares-Serono Group and Amersham International. In addition to serving as a board member of companies where he also led the executive management team, Mr. Dunbar has other significant board experience serving both public and private companies. He currently serves on the board of Accuri Cytometers, as well as the MBA Advisory Board of the College of Business at Auburn University. Mr. Dunbar received a B.S. in Electrical Engineering and an MBA from Auburn University.

Elmar R. Burchardt, M.D., Ph.D. joined Aastrom in July 2006 and was appointed Vice President, Medical Affairs in September 2006. Dr. Burchardt brings over 14 years of experience in the areas of hematopoietic stem cell transplantation, hematology and cardiology to Aastrom. Previously, Dr. Burchardt worked for Miltenyi Biotec GmbH, in Germany, where he served as Medical Director responsible for the worldwide development and market introduction strategy of 10 new clinical cell therapy products, and one of the most extensive cell therapy development programs in cardiac diseases. Prior to that time, he served as Senior Research Group Leader at the Pharmaceutical Research Center of Bayer AG, in Germany. Dr. Burchardt holds M.Sc. and Ph.D. degrees in Biochemistry, as well as an M.D. from Hannover Medical School, West Germany, and is an Associate Professor of Clinical Pharmacology at the University of Witten Herdecke, in Germany.

Ronnda L. Bartel, Ph.D. joined Aastrom in October 2006 and is currently Vice President, Technical Operations. She is responsible for the manufacturing operations of Aastrom's TRC-based cell products as well as the supporting programs in process and product development, engineering and research. Dr. Bartel is a seasoned scientist with more than 20 years of research and product development experience in the biotech, pharmaceutical, diagnostic and device sectors. During this time she held several management positions including: Senior Principal Scientist, Cell Biology at Advanced Tissue Sciences; Vice President, Scientific Development and Senior Director, Stem Cell Development at Stem Cells, Inc.; Senior Director, Science and Technology at SRS Capital, LLC; and, most recently, Executive Director, Biological Research at MicroIslet, Inc. She has also held positions in clinical development, drug delivery, business development and manufacturing. Dr. Bartel holds a Ph.D. in Biochemistry from the University of Kansas, completed postdoctoral work at the University of Michigan and received a B.A. in Chemistry and Biology from Tabor College.

Sheldon A. Schaffer, Ph.D. joined Aastrom in December 2006 as Vice President, Corporate Development & Intellectual Property. Dr. Schaffer has more than 30 years of experience in pharmaceutical and medical diagnostics industries, at both large corporations and entrepreneurial start-up companies. During his career he has been responsible for the development of U.S. and international businesses, in- and out-licensing of technology, intellectual property management, and clinical and pre-clinical drug development and drug discovery management. Most recently, Dr. Schaffer has provided business development consulting services to the pharmaceutical industry. Prior to this he served as President and CEO of Inveresk Research, N.A. He served as Vice President, Pharmaceutical Development at DepoTech Corporation, and as Vice President of Pharmaceutical Development and then as Vice President of Business Development at Cholestech Corporation, a publicly traded medical products company. Previously, Dr. Schaffer served as Director, Inflammation/Atherosclerosis Research at Ciba-Geigy Corporation, a pharmaceutical company, and held senior scientific positions at the Medical Research Division of American Cyanamid Co., a pharmaceutical company. Dr. Schaffer received his B.S. in chemistry from the University of California, Berkeley and a Ph.D. in chemistry from the University of Illinois, and served as a postdoctoral and teaching fellow at Harvard Medical School.

Frances J. Kivel joined Aastrom in November 2007 as Senior Director, Clinical Trials. Ms. Kivel has over 20 years of experience in global clinical trial development, execution and reporting from early development through post marketing. During this time, she held several management positions at Pfizer, Inc., formerly Warner-Lambert/Parke Davis. Most recently, Ms. Kivel was an associate director of R&D project management and clinical operations management within Pfizer's Global R&D organization. Her experiences include the development and approval of multiple NDA and MAA submissions, development and implementation of global organizational data standards, evaluation of strategic options within drug development, development portfolio evaluation, and the analysis and reporting of clinical trial data. At various times during her career, she has been a member of the Project Management Institute, the American Statistical Association, the Decision Analysis Affinity Group (founding member) and the Sigma Xi Scientific Research Society. Ms. Kivel received an MS in Biostatistics from the University of Michigan.

Kris M. Maly joined Aastrom in 2000 and is currently Senior Director, Communications & Administration. She is responsible for leading Aastrom's investor and public relations functions, as well as human resources. Ms. Maly has more than 20 years of business experience in public accounting and investor relations. Prior to joining Aastrom, she held various positions in the tax department at C.H. Rubin & Company. Ms. Maly received a BA in English and Art History from the University of Michigan, with additional coursework in accounting and management.

Peter C. Alain joined Aastrom in August 2007 as Senior Director, Quality Assurance. Mr. Alain has more than 25 years of Quality Assurance (QA) experience in the domestic and international pharmaceutical industries, including GMP/GLP/GCP compliance from drug discovery through post marketing. Prior to joining Aastrom, Mr. Alain held several management level positions at Pfizer, Inc., formerly Warner-Lambert/Parke-Davis, for over 26 years. Most recently, he was the Worldwide Development Quality Assurance Head for the U.S. and Latin America region within Pfizer's Global Research and Development division. During his career, he has been a member of PhRMA's Bioresearch Monitoring Steering Committee, coordinated, facilitated and mediated more than 10 successful domestic and international regulatory agency inspections, established the GMP Roundtable Forum for the production of clinical supplies and established one of the first industry QA groups to ensure electronic data integrity across GMP/GLC/GCP regulated areas. Mr. Alain received a B.S. in Biology from the University of Toronto, Canada.

Sherrill M. MacKay joined Aastrom in January 2006 and is currently Senior Director, Manufacturing. She is responsible for the global production, quality control, materials management and technology transfer required for Aastrom's TRC-based cell products. She has more than 13 years of GMP manufacturing experience in both domestic and international cell therapy operations. Prior to joining Aastrom, she was responsible for the initial development and manufacturing of a renal bio-replacement cell therapy product at RenaMed Biologics (formerly Nephros Therapeutics). In addition to maintaining internal operations, she has established and maintained international contract manufacturing relationships. Ms. MacKay received an M.S. in Biological Chemistry and a B.S in Chemistry from the University of Michigan. She has authored scientific publications in the areas of bio-replacement therapies and cell culture methodologies.

Tod Borton joined Aastrom in July of 2006 and is currently Senior Director, Engineering and Development. Mr. Borton has more than 20 years of Product Development and Quality experience in the domestic, international, biotechnology and medical device industries. Prior to joining Aastrom, Mr. Borton held the position of Director of Quality at Terumo Cardiovascular where he was responsible for quality assurance, document control, and sustaining engineering. During his time at Terumo he was instrumental in helping the company through an FDA warning letter and achieving normal status. Prior to Terumo Mr. Borton held the position of Vice President, New Product Development and Advanced Engineering at Pall Corporation where he developed and commercialized many biotech and medical filtration devices. He has authored many patents in the area of biotechnology and medical filtration device technologies. Mr. Borton received a B.S. in Plastic Technology from Eastern Michigan University.

Julie A. Caudill joined Aastrom in 1995 and is currently Controller and Corporate Secretary. She is responsible for leading Aastrom's financial reporting and accounting functions, as well as the purchasing function. Ms. Caudill has more than 20 years of business experience in the areas of accounting management and financial reporting. Prior to joining Aastrom, she held various positions in accounting management and financial reporting at KMS Fusion and PALL Corporation (formerly Gelman Science, Inc.). Ms. Caudill received a BBA in Accounting from Eastern Michigan University.

Dr. Armand Keating is Head of the Department of Medical Oncology and Hematology at Princess Margaret Hospital/Ontario Cancer Institute. He is also Professor of Medicine and Director, Division of Hematology at the University of Toronto, as well as the first incumbent of the Gloria and Seymour Chair in Cell Therapy and Transplantation. Until this year, he was also Chief, Medical Services, Princess Margaret Hospital but relinquished this position to become the first director of the Princess Margaret Hospital Cell Therapy Program. He obtained the M.D. degree from the University of Ottawa, received postgraduate training at the University of Toronto, and undertook further studies at the University of Washington and Fred Hutchinson Cancer Research Center in bone marrow transplantation. Upon his return to Toronto, he established the University of Toronto ABMT program. He was a Research Scientist of the National Cancer Institute of Canada for ten years (with research focusing on leukemic and normal hematopoiesis), and has served on numerous U.S. study sections including the National Cancer Institute Program Projects Review Committee (Subcommittee D), which he chaired. He now serves as Chair of the Translational Research Grants Committee of the Leukemia and Lymphoma Society. He was Chair of the Autologous Blood and Marrow Transplant Registry (Milwaukee), was a Councilor of the American Society of Hematology, and is the immediate past President of the American Society for Blood and Marrow Transplantation. He is also the immediate past president of the Canadian Hematology Society. Currently, he serves as Secretary and an Officer of the American Society of Hematology, and Vice-Chair of the Medical and Scientific Affairs Committee of the Leukemia and Lymphoma Society. Dr. Keating is on the editorial boards of numerous scholarly journals, and serves as co-editor of Bone Marrow Transplantation, associate editor of Biology of Blood and Marrow Transplantation, and guest section editor of Cancer. He is a past editor of Leukemia and Lymphoma .

Nelson M. Sims, Chairman since November 2007 and a Director since February 2006, most recently served as the President and Chief Executive Officer of Novavax, Inc., an international health and life science company. Prior to this, Mr. Sims held several senior executive management positions with Eli Lilly and Company until his retirement in 2001. During his 28 year tenure at Eli Lilly, Mr. Sims' positions included President of Eli Lilly Canada, Inc., Executive Director of Alliance Management, Vice President of Hybritech, Inc. and other assignments in sales and marketing management and business development. In his last position with Eli Lilly, Mr. Sims lead the Alliance Management initiative responsible for "Best in Class" partnering capabilities for research and development, commercial and development alliances. Mr. Sims received a Bachelor of Science degree in Pharmacy from Southwestern Oklahoma State University, and completed the Tuck Executive Program at the Amos Tuck School of Business at Dartmouth College. He also serves on the board of MDS, Inc.

Mr. Rubino has spent 30 years at every level of the pharmaceutical industry. Most recently he was the President and Chief Operating Officer of Pharmos Corporation where he led the transformation of the company through the acquisition of Vela Pharmaceuticals and subsequent restructuring of Pharmos to focus on its leading development compound. Prior to joining Pharmos, Mr. Rubino spent 24 years at Hoffmann-La Roche, one of the world s top ten pharmaceutical companies and a global leader in the diagnostics sector. At Roche, he was a corporate officer and member of the U.S. executive committee, holding a variety of key senior executive positions with broad management responsibilities in operations, marketing, business development, alliance management, human resources, supply chain, and corporate strategy. Mr. Rubino serves on the Board of Aastrom Biosciences and also for Rutgers Business School. Mr. Rubino holds a B.A. in Economics from Rutgers University along with a full minor in biology and chemistry.